Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Multi-centre evaluation of a comprehensive preimplantation genetic test through haplotyping-by-sequencing.

Masset H, Zamani Esteki M, Dimitriadou E, Dreesen J, Debrock S, Derhaag J, Derks K, Destouni A, Drüsedau M, Meekels J, Melotte C, Peeraer K, Tšuiko O, van Uum C, Allemeersch J, Devogelaere B, François KO, Happe S, Lorson D, Richards RL, Theuns J, Brunner H, de Die-Smulders C, Voet T, Paulussen A, Coonen E, Vermeesch JR.

Hum Reprod. 2019 Aug 1;34(8):1608-1619. doi: 10.1093/humrep/dez106.


Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity.

Mathys L, François KO, Quandte M, Braakman I, Balzarini J.

PLoS One. 2014 Jun 26;9(6):e101181. doi: 10.1371/journal.pone.0101181. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e110202.


Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.

Férir G, Hänchen A, François KO, Hoorelbeke B, Huskens D, Dettner F, Süssmuth RD, Schols D.

Virology. 2012 Nov 25;433(2):308-19. doi: 10.1016/j.virol.2012.08.007. Epub 2012 Sep 7.


Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120.

Reiser K, François KO, Schols D, Bergman T, Jörnvall H, Balzarini J, Karlsson A, Lundberg M.

Int J Biochem Cell Biol. 2012 Mar;44(3):556-62. doi: 10.1016/j.biocel.2011.12.015. Epub 2012 Jan 3.


The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.

François KO, Balzarini J.

J Biol Chem. 2011 Dec 16;286(50):42900-10. doi: 10.1074/jbc.M111.274456. Epub 2011 Oct 17.


Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.

François KO, Balzarini J.

Med Res Rev. 2012 Mar;32(2):349-87. doi: 10.1002/med.20216. Epub 2010 Jun 23. Review.


Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.

Hoorelbeke B, Huskens D, Férir G, François KO, Takahashi A, Van Laethem K, Schols D, Tanaka H, Balzarini J.

Antimicrob Agents Chemother. 2010 Aug;54(8):3287-301. doi: 10.1128/AAC.00254-10. Epub 2010 May 24.


Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.

Balzarini J, François KO, Van Laethem K, Hoorelbeke B, Renders M, Auwerx J, Liekens S, Oki T, Igarashi Y, Schols D.

Antimicrob Agents Chemother. 2010 Apr;54(4):1425-35. doi: 10.1128/AAC.01347-09. Epub 2010 Jan 4.


The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential.

François KO, Pannecouque C, Auwerx J, Lozano V, Pérez-Pérez MJ, Schols D, Balzarini J.

Antimicrob Agents Chemother. 2009 Nov;53(11):4852-9. doi: 10.1128/AAC.00811-09. Epub 2009 Aug 31.


Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanions.

Auwerx J, François KO, Vanstreels E, Van Laethem K, Daelemans D, Schols D, Balzarini J.

Antiviral Res. 2009 Jul;83(1):61-70.


Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.

Auwerx J, François KO, Covens K, Van Laethem K, Balzarini J.

Virology. 2008 Dec 5;382(1):10-9. doi: 10.1016/j.virol.2008.09.010. Epub 2008 Oct 19.


Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug development.

François KO, Auwerx J, Schols D, Balzarini J.

Mol Pharmacol. 2008 Aug;74(2):330-7. doi: 10.1124/mol.108.047621. Epub 2008 May 12.


Supplemental Content

Loading ...
Support Center